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Abstract
Background: Ventilator-associated pneumonia (VAP) is a common nosocomial infection in intensive care units
(ICUs). The objective of this study was to describe the epidemiology and microbiology of VAP in Polish ICUs from
2013 to 2015, as well as to understand how these depended on the diagnostic methods used to identify VAP
pathogens and the clinical strategy for VAP treatment.
Methods: This observational study was carried out in seven Polish adult ICUs. VAP surveillance was based on the
European Healthcare-associated Infections Surveillance Network recommendations and was defined as pneumonia
occurring more than 48 h after receiving mechanical ventilation, with symptom onset 3 days or more after the
hospital stay. Depending on the microbiological diagnostic method, VAP cases were classified as PNEU-1 (positive
quantitative culture from minimally contaminated lower respiratory tract specimen such as broncho-alveolar lavage,
protected brush or distal protected aspirate) or other VAP cases.
Results: The incidence of VAP was 8.0% and the incidence density: 12.3/1000 ventilator days. Microbiological diagnosis
was made using PNEU-1 in 80 cases (39%); over the study duration, the proportion of cases diagnosed with PNEU-1
increased from 14 to 60% (p < 0.001). The predominant etiologic agents causing VAP were Enterobacteriaceae (32.6%)
and non-fermenting Gram-negative bacteria (27.6%). The causative microbe varied significantly depending on the
diagnostic method: in cases diagnosed using PNEU-1, Staphylococcus aureus (21.3%) and Klebsiella pneumoniae (12.5%)
were the dominant organisms, whereas in other VAP cases, Acinetobacter baumannii (23.8%) was commonly observed.
The length of antibiotic treatment in cases diagnosed with PNEU-1 was shorter than for other VAP cases
(7.2 vs. 9.1 days, p < 0.005), as was the duration of hospitalization (49 vs. 51.8 days, p < 0.001). Antibiotic resistance was a
particular concern for A.baumannii isolates, which were highly resistance to imipenem (70.6%) and meropenem or
doripenem (52.9%). K. pneumoniae isolates demonstrated resistance to ampicillin (90.3%), ceftazidime (71.0%) and
third-generation cephalosporins (74.2%).
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Conclusion: A change over time was observed in the microbiological diagnostic methods used for patients with VAP.
A. baumannii was observed mainly in VAP cases diagnosed using substandard methods (non-PNEU-1). The duration of
treatment for VAP patients diagnosed properly using PNEU-1 was shorter.
Keywords: Ventilator-associated pneumonia (VAP), Healthcare-associated infections (HAI), Intensive care unit (ICU),
Poland, Acinetobacter baumannii
Background
Intensive care unit (ICU) hospitalizations impose a high
risk of acquiring healthcare-associated infection (HAIs),
most commonly nosocomial pneumonia (PNEU). In
many cases, the patient’s underlying disease and critical
condition necessitates invasive procedures and diagnos-
tics, which may contribute unavoidably to the patient’s
risk of colonization by the exogenous microbes [1–3].
One of the most common invasive procedures is intub-
ation, and an artificial respiratory tract eliminates the
physiological functions (heating, humidification and
purification) of the upper respiratory mucosa, thus in-
creasing the risk of ventilator-associated PNEU (VAP)
[4–7]. The microorganisms responsible for VAP and
their drug resistance vary between individual hospitals
wards, between regions of a country and across Europe
[8]. Thus, there is a need for local surveillance data, taking
into account a detailed analysis of etiologic agents respon-
sible for VAP, which may be highly relevant in implement-
ing local procedures for PNEU prevention [1, 9, 10].
Lower respiratory tract specimens are preferred for micro-
biological diagnosis of VAP, but invasive sampling may
not always be possible. Furthermore, the importance of
microbiological diagnosis is underestimated by Polish phy-
sicians and it remains underutilized [11, 12], despite the
fact that microbiological consult can yield better results
from antimicrobial therapy with decreased costs [13].
The main objective of this study was to describe the
epidemiology of nosocomial VAP in Polish ICU pa-
tients, and to compare these results to the European
HAI-Net program. The second aim was to understand
the microorganisms responsible for VAP, their drug
sensitivity and the interventions required to treat the
infections, as well as how these depended on the micro-
biological diagnostic method.
Methods
The analysis was carried out in seven general adult ICUs
located in southern Poland from 2013 to 2015. The in-
formation was collected through hospital participation
in a standardized program run based on the European
HAI-Net. The Healthcare-Associated Infections Surveil-
lance Network (HAI-Net) is a European network for sur-
veillance of HAIs. The network is coordinated by the
European Centre for Disease Prevention and Control
(ECDC), an EU agency established in 2005and aimed at
strengthening Europe’s defenses against infectious diseases.
Participation in HAI-Net is voluntary and confidential for
ICUs. In Poland, the coordinator of HAI-Net was the
Polish Society of Hospital Infections, a non-governmental
organization. Detailed descriptions of data collection sys-
tems, study units, epidemiology of bloodstream infections
and their microbiology have been previously published else-
where [14, 15]. All of the units participating in the study
were part of non-teaching multi-profile hospitals, with an
average number of 414 beds (range: 224–669). The average
full time-equivalent nurse per bed ratio was 2.6. Nearly all
six of the surveyed units were trauma and medical ICUs
without cardiac surgery, neurosurgery or oncology (no im-
munocompromised, hematological and/or transplant pa-
tients); one unit was a surgical ICU. In terms of ICU
type and patient characteristics, the study units were
typical Polish ICUs. Care bundles were not used for
ventilated patients.
The study excluded ICU patients whose hospital stay
was shorter than 2 days and patients who showed symp-
toms of infection within 2 days of admission. The intub-
ation utilization ratio was 0.79.
PNEU was diagnosed and classified based on the uni-
form definitions issued by the ECDC for all ICUs covered
by surveillance. Only cases involving VAP were included
in the analysis. VAP was defined according to the ECDC
as PNEU (diagnosed using clinical and microbiological
criteria) occurring more than 48 h after patients received
mechanical ventilation, with symptom onset 3 days or
more after the hospital stay [16, 17]. Depending on the
microbiological diagnostic method, VAP cases were classi-
fied as PNEU-1 (minimally contaminated lower respira-
tory tract sample with quantitative culture), PNEU-2
(non-protected sample, such as endotracheal aspirate,
with quantitative culture), PNEU-3 (alternative microbio-
logical criteria such as positive blood culture), PNEU-4
(sputum bacteriology or non-quantitative), or PNEU-5 (no
microbiological documentation) [16, 17].
The following epidemiological measures were used: (i)
the cumulative incidence of VAP was calculated by
dividing the number of VAP cases by the number of pa-
tients admitted to the ICU and multiplying by 100; (i)
the density incidence of VAP was calculated by dividing
the number of VAP cases by the number of ventilator
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days (pds) and multiplying by 1000; and (iii) the case
fatality rate was calculated by dividing the number of
deaths of VAP cases by the total number of VAP cases
and multiplied by 100. Statistical analysis of the data
was performed using SPSS software (SPSS – Statistical
Package for the Social Sciences) STATISTICS 24,
Armonk, NY, USA. For statistical analysis of ordinal or
dichotomous data, information on the number and per-
centage of individuals was used. In order to compare
differences between the duration of antibiotic treat-
ment and duration of hospital stay, the mean, median
(Me), standard deviation (SD), 95% confidence interval
(95% CI), minimum and maximum were calculated. For
ordinal and nominal variables, Pearson’s chi-square (χ2)
test was used. Statistical significance was assumed at a
level of p < 0.05.
Ethics approval and consent to participate
This study was approved by the Bioethics Committee of
Jagiellonian University (approval no. KBET /122.6120.118.
2016 from 25.05.2016). All data used in this study were
anonymized prior to analysis.
Results
Over the period analyzed, there were 2547 patients hospi-
talized for over 48 h in the seven Polish ICUs and 205 VAP
cases. The number of patients hospitalized in each ICU
ranged from 206 to 628. The cumulative VAP incidence
was 8.0% and the incidence density was 12.3/1000pds.
Microbiological diagnosis was made in 80 VAP cases (39%)
using PNEU-1and over the study duration, the proportion
of VAP cases diagnosed using PNEU-1increased from 14
to 60% (p < 0.001) (Fig. 1).
The average time from admission to VAP diagnosis
was 26 days (SD 91.8; Me 9, 95%CI 13.5–38.7,). The
average duration of hospitalization of VAP cases was
51 days (SD 97.1; Me 31, 95% CI 37.2–64.4). The dur-
ation of hospitalization was not significantly shorter for
VAP cases diagnosed using PNEU-1 (49 days, SD 89.1;
Me 31, 95% CI 29.3–69.2) compared with other VAP
cases (51.8 days, SD 102.3; Me 31, 95% CI 33.3–70.4,).
The predominant etiologic agents responsible for VAP
were Enterobacteriaceae (32.6%) and non-fermenting
Gram-negative bacteria (27.6%). The causative microbe
varied significantly depending on the diagnostic method.
In VAP cases diagnosed using PNEU-1, Staphylococcus
aureus (21.3%) and Klebsiella pneumoniae (21.3%) were
the dominant organisms, whereas in other VAP cases,
Acinetobacter baumannii (30.2%) and K. pneumoniae
(15.9%) were commonly observed (Table 1).
Antibiotic resistance was a particular concern for A.
baumannii isolates, which were highly resistant to carba-
penems, including imipenem (24 strains, 70.6%) and mero-
penem or doripenem (18 strains, 52.9%). K. pneumoniae
isolates were commonly resistant to ampicillin (28 strains,
90.3%), ceftazidime (22 strains, 71.0%) and third-generation
cephalosporins (23 strains, 74.2%) (Table 2).
VAP cases were typically treated using beta-lactams
such as third-generation cephalosporins (18.8%), carba-
penems (18.1%), and penicillins (16.1%). Subsequent
treatments included polymyxins (colistin, 14.1%); amino-
glycosides (amikacin, 10.7%) and other drugs (Table 3).
The length of antibiotic treatment in VAP cases
diagnosed with PNEU-1 was significantly shorter than
for other VAP cases (7.2 days vs. 9.1 days, p < 0.05)
(Table 4).
Fig. 1 Diagnostic category of ICU-acquired pneumonia, 2013–2015
Wałaszek et al. BMC Infectious Diseases  (2018) 18:308 Page 3 of 9
The overall VAP case fatality case rate was 13.6% and fa-
tality case rate was variably associated with infection:
PNEU was the direct cause of death in 16 cases (fatality
case rate 7.8%), was indirectly connected with death in six
cases (2.9%), and was not associated with death in six
cases (2.9%). There was no statistically significant differ-
ence between fatality case rate and microbiological diag-
nostic method (PNEU-1 diagnosed invasively vs. other
types of VAP) (p = 0.08).
Discussion
According to 2007 data from the European Union, the
incidence of VAP was 7% and the incidence density was
8.0/1000 pds [5], slightly lower values than the figures
reported in this study. An earlier Polish multicenter
study conducted from 2002 to 2003 reported VAP inci-
dence as 6% [18]. However, newer data from 2010 to
2014 and 2015 confirm higher VAP incidence at ap-
proximately 9% [3]. The trend toward increasing VAP
incidence over the last 10 years may result from im-
proved sensitivity in case detection related to the greater
experience of infection control teams, which appeared in
Polish hospitals only around the year 2000 [19]. Still,
taking into consideration the basic risk factors for VAP
(mechanical ventilation and intubation utilization ratio),
VAP incidence in Poland was higher than the EU
average [5].
No prior studies in Poland addressed the microbio-
logical diagnostic methods that are most commonly
employed for VAP, but on the basis of our results, it
seems that quantitative cultures from minimally con-
taminated lower respiratory tract specimens were rela-
tively rarely applied. In the United States, around 60%
of VAP cases in medical ICUs are microbiologically di-
agnosed using state-of-the-art testing methods [20],
and in the United Kingdom this figure is around 80%
[5]. Fortunately, our data also indicated an increasing
proportion over time (14% vs. 60%) of VAP cases diag-
nosed using PNEU1(based on invasive sampling of
material, mainly broncho-alveolar lavage) with a simul-
taneous decrease in the numbers of VAP cases diag-
nosed using other methods. These changes show that
the awareness of VAP diagnostic methods in ICUs is
changing for the better, but also reflects better equip-
ment in the ICUs (including bronchoscopes, making
broncho-alveolar lavage possible). Unfortunately, VAP
Table 1 Microorganisms isolated in VAP depending on the employed method of taking the material for microbiological diagnostics,
Polish ICUs 2013–2015
VAP PNEU-1a Other VAP casesb Total
Gram-positive cocci n(%) 35 (19.3)
Staphylococcus aureus 17 (21.3) 10 (9.9) 27 (16.1)
Coagulase-Negative Staphylococci 0 (0.0) 1 (1.0) 1 (0.6)
Enterococcus spp. 1 (1.3) 1 (1.0) 2 (1.2)
Streptococcus pneumoniae 4 (5.0) 1 (1.0) 5 (3.0)
Enterobacteriaceae n(%) 59 (32.6)
Citrobacter spp. 0 (0.0) 1 (1.0) 1 (0.6)
Enterobacter spp. 1 (1.3) 2 (2.0) 3 (1.8)
Escherichia coli 5 (6.3) 7 (6.9) 12 (7.1)
Klebsiella pneumoniae 17 (21.3) 16 (15.8) 31 (18.5)
Proteus spp. 2 (2.5) 4 (4.0) 6 (3.6)
Seratia spp. 5 (6.3) 1 (1.0) 6 (3.6)
Non-fermenting Gram-negative bacteria n(%) 50 (27.6)
Acinetobacter baumannii 10 (12.5) 24 (23.8) 34 (20.2)
Pseudomonas aeruginosa 8 (10.0) 2 (2.0) 10 (6.0)
Stenotrothomonas maltophilia 1 (1.3) 1 (1.0) 2 (1.2)
Hemophilus spp. 0 (0.0) 4 (4.0) 4 (2.4)
Other n(%) 37 (20.4)
Other bacteria 20 (25.0) 17 (16.8) 20 (22.0)
Total n(%) 80 (100.0) 101 (100.0) 181 (100.0)
VAP Ventilator-Associated Pneumonia
aPNEU-1: pneumonia documented by invasive diagnostics, minimally contaminated lower respiratory tract sample with quantitative culture
bOther VAP cases, documented by: PNEU-2 non-protected sample with quantitative culture; PNEU-3 alternative microbiological criteria; PNEU-4 sputum
bacteriology or non-quantitative culture
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cases without positive microbiology were detected
three times more often (14% vs. 5%) in the ICU units
studied here than in countries of the European Union [5].
In the Polish ICUs studied here, a large burden of in-
fection by Gram-negative bacilli was documented. A.
baumannii in particular was responsible for as many as
1/5 cases, and was much more frequently observed than
in most European countries [21]. The substantial preva-
lence of Acinetobacter has also been confirmed by other
Polish reports [22–24]. A. baumannii is not commonly
regarded as a major VAP pathogen and because only a
minority of VAP microbiological diagnoses were made
properly in Polish ICUs, it is difficult to know whether
the high prevalence of A. baumannii may have resulted
from environmental contamination. On the other hand,
antimicrobial drug resistance in the tested samples mainly
concerned Gram-negative bacilli (e.g., carbapenem-resistant
A. baumannii and third-generation cephalosporin-resistant
K. pneumoniae). The data from the ECDC from 2012 on-
wards point to a significantly lower overall proportion of
drug-resistant isolates in Europe. For instance, non-invasive
K. pneumoniae isolates were, on average, three times less
resistant to third-generation cephalosporins than the iso-
lates described in our study (26% vs. 74.2%) [21].
Alp and Damani [25], in their studies of nosocomial
infection incidence in low-to-middle income countries,
attributed part of the burden of disease to insufficient
surveillance of multi-drug resistant organisms. A Human
Development Index report from 2015 ranked Poland
36th out of 169 countries, placing Poland among the 25%
richest countries in the world. Hence, the high percentage
of drug-resistant strains observed in our study is unusual
and requires further explanation. Poland underwent a sys-
temic transformation as late in 1989 and, subsequently,
legal regulations made it possible to build a nosocomial
infection surveillance system. However, this system now
Table 2 Antimicrobial resistance in Polish ICUs by VAP, 2013–2015
Number of isolates Antibiotic or resistant codes Non susceptible N (%)
Gram-positive cocci
Staphylococcus aureus 27 MRSA 2 (7.4)
ampicillin 0 (0)
glycopeptides 0 (0)
Enterobacteriaceae
Escherichia coli 12 ampicillin 7 (58.3)
ceftazidime 3 (25.0)
cefotaxim/ceftriaxone 3 (25.0)
imipenem 1 (8.3)
meropenem/doripenem 0 (0)
ESBL 1 (8.3)
Klebsiella pneumoniae 31 ampicillin 28 (90.3)
ceftazidime 22 (71.0)
cefotaxim/ceftriaxone 23 (74.2)
imipenem 0 (0)
meropenem/doripenem 0 (0)
ESBL 15 (48.4)
Non-fermenting Gram-negative bacteria
Acinetobacter baumannii. 34 imipenem 24 (70.6)
meropenem/doripenem 18 (52.9)
colistin 0 (0.0)
sulbactam 14 (41.2)
Pseudomonas aeruginosa 10 piperacillin 2 (20.0)
ceftazidime 2 (20.0)
colistin 0 (0.0)
imipenem 2 (20.0)
meropenem/doripenem 2 (20.0)
ESBL Extended Spectrum Beta-lactamase, MRSA methicillin-resistant Staphylococcus aureus, VAP Ventilator-Associated Pneumonia
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Table 3 Distribution of antimicrobials used for Ventilator-Associated Pneumonia treatment in studied ICUs, 2013–2015, no data: 56 (27%)
Antimicrobial agents ATC codes Antibiotic N (%)
Beta-lactam antibacterials, penicillins (16.1% of all antimicrobials) 24 (100)
Penicillins, with extended spectrum J01CA J01CA12 Piperacillin 5 (20.8)
Beta lactamase resistant penicillins J01CF J01CF02 Cloxacillin 5 (20.8)
Combinations of penicillins incl. Beta-lactamase inhibitors J01CR J01CR02 Amoxicillin and enzyme inhibitor 14 (58.3)
Other beta-lactam antibacterials (37.6% of all antimicrobials) 56 (100)
Second-generation cephalosporins J01DC J01DC03 Cefamandole 1 (1.8)
Third-generation cephalosporins J01DD J01DD02 Ceftazidime 3 (5.4)
JO1DD04 Ceftriaxone 4 (7.1)
JO1DD01 Cefotaxime 21 (37.5)
Carbapenems J01DH J01DH02 Meropenem 16 (28.6)
J01DH51 Imipenem and enzyme inhibitor 11 (19.6)
Other antibacterials (18.8% of all antimicrobials) 28 (100)
Glycopeptide antibacterials J01XA J01XA01 Vancomycin 6 (21.4)
J01XA02 Teicoplanin 1 (3.6)
Polymyxins J01XB J01XB01 Colistin 21 (75.0)
Sulfonamides and trimethoprim (4.0% of all antimicrobials) 6 (100)
Combinations of sulfonamides and trimethoprim, incl.
Derivatives
J01EE J01EE01 Sulfamethoxazole and trimethoprim 6 (100.0)
Aminoglycoside antibacterials (10.7% of all antimicrobials) 16 (100)
Aminoglycosides J01GB06 Amikacin 16 (100.0)
Quinolone antibacterials (9.4% of all antimicrobials) 14 (100)
Quinolone J01MA J01MA02 Ciprofloxacin 7 (50.0)
J01MA12 Levofloxacin 7 (50.0)
Macrolides, lincosamides and streptogramines (1.3% of all antimicrobials) 2 (100)
Lincosamides J01FF J01FF01 Clindamycin 2 (100.0)
Antimycotics for systemic use (2.0% of all antimicrobials) 3 (100)
Triazole derivatives J02AC01 Fluconazole 3 (100.0)
Total 149 (100.0)
Table 4 Duration of antibiotic treatment and duration of hospital stay depending on the employed method of taking the material
for microbiological diagnostics of VAP, Polish ICUs 2013–2015
Duration of antibiotic treatment Length of ICU stay
PNEU-1a Other VAP casesb PNEU-1a Other VAP casesb
Average (95% CI) (days) 7 (6,8) 9 (8,10) 49 (29,69) 52 (33,70)
Median 7 8 31 31
Standard deviation 3 4 89 102
Minimum 1 3 11 2
Maximum 15 21 781 744
Pearson’s chi-square (χ2 = 8,35, df = 2, p < 0.05) (χ2 = 114, df = 69, p < 0.001)
ICU Intensive Care Unit, VAP Ventilator-Associated Pneumonia
aPNEU-1: pneumonia documented by invasive diagnostics, minimally contaminated lower respiratory tract sample with quantitative culture
bOther VAP cases, documented by: PNEU-2 non-protected sample with quantitative culture; PNEU-3 alternative microbiological criteria; PNEU-4 sputum
bacteriology or non-quantitative culture; PNEU-5 no microbiological documentation
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seems to be in some extent ineffective [19]. Ider et al. [26]
studied countries of the former Eastern bloc that under-
went dramatic transformations and noticed certain prob-
lems in the nosocomial infection surveillance systems of
these countries, including poor commitment, lack of re-
sources, lack of knowledge, and under-reporting of infec-
tion statistics. Such situations may result in insufficient
prevention and over-treatment of nosocomial infections,
which, in turn, can generate antimicrobial resistance.
Our study demonstrates the importance of using ap-
propriate microbiological diagnostic methods in cases of
VAP. Our results, showing that the length of antibiotic
treatment was significantly shorter when diagnosis was
made via quantitative culture from minimally contami-
nated lower respiratory tracts specimens, are in agree-
ment with those of Fagon et al. who showed that VAP
cases diagnosed in this manner require shorter antibiotic
treatments and have lower fatality case rate [27]. In a
study by Martin-Loeches et al. [28], treatment with an
appropriate antibiotic was associated with longer sur-
vival in ICUs, and in patients without microbiological
confirmation, more antibiotics were required.
The results of our study also showed that patients di-
agnosed with PNEU-1 stayed in the ICU for a signifi-
cantly shorter time (about 2 days less) than other VAP
patients. Taking into account the costs of ICU
hospitalization and the wider circumstances related to
healthcare financing, this is a significant benefit both
for individual hospitals and for the entire healthcare
financing system. In a study of prolonged ICU
hospitalization of patients with nosocomial PNEU and
its related costs, it was shown that these costs are 40
times higher in Poland than the total costs of out-
patient pneumonia [29].
The results of our study indicate the extremely import-
ant role of microbiological diagnostic methods in infection
control programs. The correct choice of sample material
for microbiological diagnosis, as well as optimal methods
(as confirmed by a study in a Polish NICU [30]), yields
quick and reliable information about the etiological agent
and results in a shorter duration of treatment, a shorter
length of hospitalization and a lower cost of treatment. At
the same time, our results indicate that optimal methods
of microbiological diagnosis are insufficiently applied in
Poland. This is part of a wider problem in Polish hospitals,
which has also been confirmed by studies in different pa-
tient population [30–32]. In Polish hospitals, this problem
may be related to the lack of physician-microbiologists
[33]. Microbiologists or infectious disease physicians are
often requested for consultations from other specialty de-
partments with the aim to optimize care for patients with
multiple morbidities. Thus, they play a significant role in
hospital infection control and antimicrobial stewardship.
Studies have shown that microbiological expertise
confers significant benefits to other hospital depart-
ments including ICUs [22, 34, 35].
This study had some limitations. The first was that it
was conducted in a relatively small group of seven
ICUs. Most of these ICUs hospitalized patients with
similar conditions, but no detailed information was
available on comorbidities and no APACHE scores or
other health scores were assigned to patients. Another
limitation is that, although all study units used the
same protocol, there was no external validation of in-
fection detection. Additionally, the protocol did not re-
quire gathering detailed data on mechanical ventilation,
there were no unique standards of cooperation with
microbiology labs, and isolated strains were not banked
(and hence no detailed characteristics of etiological
agents were available).
Conclusions
VAP incidence, duration of hospital stay, and fatality
case rate in Polish ICUs did not differ from other Euro-
pean countries. Participation in a multicenter infection
surveillance system increased the proportion of VAP
cases diagnosed using microbiological tests of samples
obtained with a method minimalizing the risk of sample
contamination.
The reported microbial causes of VAP and their anti-
microbial resistance varied significantly depending on the
microbiological diagnostic technique. A. baumannii isolates
were observed primarily in VAP cases diagnosed using sub-
standard microbiological techniques – without positive
quantitative culture or corresponding semi-quantitative cul-
ture result from minimally-contaminated LRT specimen.
The length of antibiotic therapy for VAP cases was signifi-
cantly shorter when microbiological diagnosis was made
using materials collected using a method minimalizing the
risk of sample contamination.
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